





Page 1 of 1

Form PTO-1449

U.S. Department of Commerce  
Patent and Trademark OfficeAtty. Docket No.  
60390-G/JPW/GJG/JBCSerial No.  
09/728,616INFORMATION DISCLOSURE CITATION  
(Use several sheets if necessary)

Applicants: Arlindo L. Castelhana, et al.

Filing Date  
December 1, 2000Group  
1623

## U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
CD	20 02 00 28 7 8 2	3/7/02	Castelhana et al.			
CD	20 02 00 58 6 6 7	5/16/02	Castelhana et al.			
CD	20 03 00 36 5 4 5	2/20/03	Castelhana et al.			
CD	20 03 00 45 5 3 6	3/6/03	Castelhana et al.			
CD	20 03 00 73 7 0 8	4/17/03	Castelhana et al.			

## FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Subclass	Translation
					Yes No
WO 9 5 1 9 7 7 4	7/27/95	PCT (Exhibit 1).			

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER

DATE CONSIDERED

7/15/2004

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



RECEIVED  
NOV 20 2003  
TECH CENTER 1800/2800  
Page 1 of 13

Form PTO-1449

U.S. Department of Commerce  
Patent and Trademark Office

Atty. Docket No.  
60390-G/JPW/GJG/JBC

Serial No.  
09/728,616

INFORMATION DISCLOSURE CITATION  
(Use several sheets if necessary)

Applicants: Arlind L. Castelhan, et al.

Filing Date  
December 1, 2000

Group

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
(2)	5 2 9 6 4 8 4	3/22/94	Coghlan, M. J. et al. (Exhibit 1);			
	5 4 0 9 9 3 0	4/25/95	Spada, A. P. et al. (Exhibit 2);			
	5 5 1 6 8 9 4	5/14/96	Reppert S. M. (Exhibit 3);			
	5 5 8 0 8 7 0	12/3/96	Barker, A. J. et al. (Exhibit 4);			
	5 6 4 6 1 3 0	7/8/97	Shi, G. H. (Exhibit 5);			
	5 6 8 1 9 4 1	10/28/97	Cook, P. D. et al. (Exhibit 6);			
	5 7 1 0 1 5 8	1/20/98	Myers, M. R. et al. (Exhibit 7);			
	5 7 1 4 4 9 3	2/3/98	Myers, M. R. et al. (Exhibit 8);			
	5 7 2 1 2 3 7	2/24/98	Myers, M. R. et al. (Exhibit 9);			
	5 7 4 7 4 9 8	5/5/98	Schnur, R.C. et al. (Exhibit 10);			
	5 7 8 0 4 5 0	7/14/98	Shade, D. L. (Exhibit 11);			
(2)	5 9 6 2 4 5 8	10/5/99	Lohmann, et al. (Exhibit 12);			

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation
						Yes No
(2)	WO 9 4 1 7 0 9 0	8/4/94	PCT (Exhibit 13);			
(2)	WO 9 5 1 1 6 8 1	5/4/95	PCT (Exhibit 14);			
(2)	WO 9 5 2 0 5 9 7	8/3/95	PCT (Exhibit 15);			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)


EXAMINER

DATE CONSIDERED

2/6/04

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



RECEIVED

NOV 20 2003

TECH CENTER 1600/2900

Page 2 of 13

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 60390-G/JPW/GJG/JBC	Serial No. 09/728,616
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		Applicants: Arlindo L. Castelhana, et al.	
		Filing Date December 1, 2000	Group

## U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

## FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	N
(P)	WO 96 19 47 8	6/27/96	PCT (Exhibit 16);				
	WO 97 05 13 8	2/13/97	PCT (Exhibit 17);				
	WO 97 33 87 9	9/18/97	PCT (Exhibit 18);				
	WO 98 08 38 2	3/5/98	PCT (Exhibit 19);				
	WO 98 22 46 5	5/28/98	PCT (Exhibit 20);				
	WO 99 06 05 3	2/11/99	PCT (Exhibit 21);				
	WO 99 08 46 0	2/18/99	PCT (Exhibit 22);				
	WO 99 33 81 5	7/8/99	PCT (Exhibit 23);				
	WO 99 42 09 3	8/26/99	PCT (Exhibit 24);				
	EP 03 22 24 2	6/28/89	EPO (Exhibit 25);				
	EP 07 29 75 8	4/9/96	EPO (Exhibit 26);				
	JP 92 91 08 9	5/11/99	Japan (Abstract Only) (Exhibit 27);				

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Blazynski C., (1990) "Discrete Distributions of Adenosine Receptors in Mammalian Retina", <u>Journal of Neurochemistry</u> , 53: 648-655 (Exhibit 28);
	Braas K.M., et al., (1987) "Endogenous adenosine and adenosine receptors localized to ganglion cells of the retina", <u>Proceedings of the National Academy of Science</u> , 84: 3906-3910 (Exhibit 29);
(P)	Bradford M. M., (1976) "A Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye Binding", <u>Anal. Biochem.</u> , 72: 248-254 (Exhibit 30);

EXAMINER	DATE CONSIDERED 2/6/04
----------	------------------------

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



RECEIVED  
NOV 20 2003  
TECH CENTER 1600/2900

Page 3 of 13

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 60390-G/JPW/GJG/JBC		Serial No. 09/728,616	
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				Applicants: Arlindo L. Castelbano, et al.			
				Filing Date December 1, 2000		Group	
U.S. PATENT DOCUMENTS							
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
FOREIGN PATENT DOCUMENTS							
		Document Number	Date	Country	Class	Subclass	Translation Yes No
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
④		Broach, J. R., et al., (1983) "Vectors for high level, inducible expression of cloned genes in yeast", in <u>Experimental Manipulation of Gene Expression</u> . M. Inouye (ed)., Academic Press, New York, 83-117 (Exhibit 31);					
		Chen, Y. L., et al., (1997) "Synthesis and Oral Efficacy of a 4-(Butylethylamino)pyrrolo[2,3-d]pyrimidine: A Centrally Active Corticotropin-Releasing Factor <sub>1</sub> Receptor Antagonist", <u>J. Med. Chem.</u> , 40: 1749-1754, (Exhibit 32);					
		Cheng, Y. and Prusoff, W. H. (1973) "Relationship Between The Inhibition Constant ( $K_i$ ) And The Concentration Of Inhibitor Which Causes 50 Per Cent Inhibition ( $I_{50}$ ) Of An Enzymatic Reaction", <u>Biochem. Pharmacol.</u> , 22: 3099-3109 (Exhibit 33);					
		Christianson, T. W. et al., (1992) "Multifunctional yeast high-copy-number shuttle vectors", <u>Gene</u> , 110: 119-122 (Exhibit 34);					
②		Duzic, E. et al., (1992) "Factors Determining the Specificity of Signal Transduction by Guanine Nucleotide-binding Protein-coupled Receptors", <u>J. Biol. Chem.</u> , 267: 9844-9851 (Exhibit 35);					
EXAMINER		DATE CONSIDERED 2/6/04					
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							



NOV 20 2003  
TECH CENTER 1600/2800

Page 4 of 13

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 60390-G/JPW/GJG/JBC		Serial No. 09/728,616	
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				Applicants: Arlindo L. Castelhana, et al.			
				Filing Date December 1, 2000		Group	
U.S. PATENT DOCUMENTS							
Examiner (Initial)		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
FOREIGN PATENT DOCUMENTS							
		Document Number	Date	Country	Class	Subclass	Translation Yes No
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
(6)		Feoktistove, I. et al., (1998) "Adenosine A <sub>2B</sub> receptors: a novel therapeutic target in asthma?", <u>TIPS</u> 19: 148-153 (Exhibit 36);					
		<del>GenBank accession numbers S45235 and S56143 (Exhibit 37);</del>					
		<del>GenBank accession # S46950 (Exhibit 38);</del>					
(12)		Kang, Y. et al., (1990) "Effects of Expression of Mammalian G $\alpha$ and Hybrid Mammalian-Yeast G $\alpha$ Proteins on the Yeast Pheromone Response Signal Transduction Pathway", <u>Mol. Cell. Biol.</u> , 10: 2582-2590 (Exhibit 39);					
		Muller, C. E. and Stein, B. (1996) "Adenosine Receptor Antagonist: Structure and Potential Therapeutic Applications", <u>Current Pharmaceutical Design</u> , 2: 501-530 (Exhibit 40);					
		Muller, C. E. (1997) "A <sub>1</sub> -Adenosine Receptor Antagonists", <u>Exp. Opin. Ther. Patents</u> 7(5): 419-440 (Exhibit 41);					
(13)		Muller, C. E., et al., (1997) "Synthesis and Structure-Activity Relationships of 3,7-Dimethyl-1-propargylxanthine Derivatives, A <sub>2A</sub> -Selective Adenosine Receptor Antagonists", <u>J. Med. Chem.</u> , 40: 4396-4405 (Exhibit 42);					
EXAMINER		DATE CONSIDERED 2/6/04					
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



RECEIVED  
NOV 20 2003  
TECH CENTER 1600/2900

Page 6 of 13

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 60390-G/JPW/GJG/JBC	Serial No. 09/728,616
		Applicants: Arlindo L. Castelhana, et al.	
		Filing Date December 1, 2000	Group

INFORMATION DISCLOSURE CITATION  
(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
JP	5 6 3 9 9 1 3	6/17/97	Lidor, R. et al. (Exhibit 50);			
	5 8 3 4 6 0 9	11/10/98	Horne, D. A. et al. (Exhibit 51);			
	5 8 7 7 2 1 8	3/2/99	Herzig, Y. et al. (Exhibit 52);			
	5 8 7 7 2 2 1	3/2/99	Cohen, S. et al. (Exhibit 53);			
	5 8 8 0 1 5 9	3/9/99	Herzig, Y. et al. (Exhibit 54);			
	5 9 1 4 3 4 9	6/22/99	Cohen, S. et al. (Exhibit 55);			
	5 9 9 4 4 0 8	11/30/99	Cohen, S. et al. (Exhibit 56);			
	6 1 0 3 8 9 9	8/15/00	Horne, D. A. et al. (Exhibit 57);			

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
	WO 9 9 6 2 5 1 8	12/9/99	PCT (Exhibit 49);				
	WO 9 4 2 4 1 3 6	10/27/94	PCT (Exhibit 58);				
	WO 9 5 1 8 6 1 7	7/13/95	PCT (Exhibit 59);				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER

DATE CONSIDERED

2/6/04

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.





RECEIVED

NOV 20 2003

TECH-CENTER 1600/2900

Page 7 of 13

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 60390-G/JPW/GJG/JBC		Serial No. 09/728,616							
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				Applicants: Arlindo L. Castelhana, et al.									
				Filing Date December 1, 2000		Group							
U.S. PATENT DOCUMENTS													
Examiner Initial		Document Number		Date	Name	Class	Subclass	Filing Date if Appropriate					
P		3	0	3	7	9	8	0	6/5/62	Hitchings, G. H. et al. (Exhibit 60);			
FOREIGN PATENT DOCUMENTS													
		Document Number		Date	Country	Class	Subclass	Translation					
								Yes	No				
		WO	9	3	2	0	0	7	8	10/14/93	PCT (Exhibit 61);		
		WO	9	4	1	3	6	7	6	6/23/94	PCT (Exhibit 62);		
		WO	9	5	1	9	9	7	0	7/27/95	PCT (Exhibit 63);		
		WO	9	8	0	7	7	2	6	2/26/98	PCT (Exhibit 64);		
		WO	9	8	5	7	6	5	1	12/23/98	PCT (Exhibit 65);		
		EP	0	5	1	4	5	4	0	11/25/92	EPO (Exhibit 66);		
		EP	0	6	8	2	0	2	7	11/15/95	EPO (Exhibit 67);		
		EP	0	7	2	9	7	5	8	9/4/96	EPO (Exhibit 68);		
		EP	0	7	7	3	0	2	3	5/14/97	EPO (Exhibit 69);		
		GB	9	1	5	3	0	3		1/9/63	GB (Exhibit 70);		
		DE	3	1	4	5	2	8	7	5/19/83	DE (Exhibit 71);		
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)													
		Iwamura, H. et al. (1996) "Quantitative Aspects of the Receptor Binding of Cytokinin Agonists and Antagonists" <u>J. Med. Chem.</u> , 26: 838-844 (Exhibit 72);											
		Jorgensen, A. et al. (1985) "Synthesis of 7H-Pyrrolo[2,3-d]pyrimidin-4-amines" <u>Liebigs. Ann. Chem.</u> , Pages 142-148 (Exhibit 73);											
		Kiichiro, K. et al. "Synthesis of pyrazinecarboxylic acid derivs. - (II) derivs. of 3-aminopyrazinecarboxylic acid" (Abstract only) (Exhibit 74);											
		Muller, E. C. et al. (1996) "Chiral Pyrrolo[2,3-d]pyrimidine and Pyrimido[4,5,-b]indole Derivatives: Structure-Activity Relationships of Potent, Highly Stereoselective A <sub>1</sub> -Adenosine Receptor Antagonist" <u>J. Med. Chem.</u> , 39: 2482-2491 (Exhibit 75);											
EXAMINER						DATE CONSIDERED		2/6/04					
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.													




RECEIVED

NOV 20 2003

TECH CENTER 1600/2900

Page 8 of 13.

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office		Att. Docket No. 60390-GJPW/GJG/JBC		Serial No. 09/728,616	
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				Applicants: Arlindo L. Castelhana, et al.			
				Filing Date December 1, 2000		Group	
U.S. PATENT DOCUMENTS							
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
FOREIGN PATENT DOCUMENTS							
		Document Number	Date	Country	Class	Subclass	Translation Yes No
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
4		Muller, C. E. et al. (1990) "7-Deaza-2-phenyladenines: Structure-Activity Relationships of Potent A1 Selective Adenosine Receptor Antagonists" <u>J. Med. Chem.</u> , 33: 2822-2828 (Exhibit 76);					
		Venugopalan, B. et al. (1998) "Synthesis of 6,7-Dimethoxypyrimido[4,5-b]-indoles as Potential Antihypertensive Agents" <u>J. Heterocyclic Chem.</u> , 25: 1633-1639 (Exhibit 77); and					
		West, R. A. et al. (1961) "2-Alkyl(aryl)-and 2,7-Dimethyl-4-substituted Aminopyrrolo[2,3-d]pyrimidines" <u>J. Org. Chem.</u> , 26: 3809-3810 (Exhibit 78);					
		DeNinno, M.P. in <u>Annual Reports in Medicinal Chemistry</u> , Vol. 33, (Academic Press: San Diego, 1998), pp. 111-120 (Exhibit 79);					
7		Hart, H. et al., <u>Organic Chemistry, A Short Course</u> , (Houghton Mifflin: 1995), p. 121 (Exhibit 80);					
EXAMINER	DATE CONSIDERED			2/6/04			
* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							



RECEIVED  
NOV 20 2003  
TECH CENTER 1600/2900

Page 9 of 13

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 60390-G/JPW/GJG/JBC		Serial N. 09/728,616							
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				Applicants: Arlindo L. Castelano, et al.									
				Filing Date December 1, 2000		Group							
U.S. PATENT DOCUMENTS													
Examiner Initial		Document Number		Date	Name	Class	Subclass	Filing Date if Appropriate					
GA		5	6	4	6	1	5	6	7/8/97	Jacobson, et al. (Exhibit 81);			
		5	7	8	0	4	8	1	7/14/98	Jacobson, et al. (Exhibit 82);			
		3	9	1	0	9	1	3	10/7/75	Kim, et al. (Exhibit 83)			
FOREIGN PATENT DOCUMENTS													
		Document Number		Date	Country	Class	Subclass	Translation					
								Yes	No				
		WO	0	0	0	3	7	4	1	1/27/00	PCT (Exhibit 84);		
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)													
		Abbracchio M., et al., (1999) "Brain Adenosine Receptors as Targets for Therapeutic Intervention in Neurodegenerative Diseases", Ann. NY. Acad. Sci., 890: 79-92 (Exhibit 85);											
		Abbracchio M., et al., (1997) "Modulation of Apoptosis by Nervous System: a Possible Role for the A <sub>3</sub> Receptor", Ann. NY. Acad. Sci., 825: 11-22 (Exhibit 86);											
		Baraldi P., et al., (2000) "New potent and selective human adenosine A <sub>3</sub> receptor antagonists", Tips, 21: 456-459 (Exhibit 87);											
		Brand A., et al., (2001) "Adenosine A <sub>1</sub> and A <sub>3</sub> receptors mediate inhibition of synaptic transmission in rat cortical neurons", Neuropharmacology, 40: 85-95 (Exhibit 88);											
		Casavola V., et al., (1998) "Adenosine A <sub>3</sub> receptor activation increases cytosolic calcium concentration via calcium influx in A6 cells", Drug Development Research, 43 (1): 62 (Exhibit 89)											
EXAMINER		DATE CONSIDERED 7/6/04											
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.													



NOV 20 2003

TECH CENTER 1600/2900

Page 10 of 13

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 60390-G/JPW/GJG/JBC		Serial No. 09/728,616	
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				Applicants: Arlindo L. Castelhana, et al.			
				Filing Date December 1, 2000		Group	
U.S. PATENT DOCUMENTS							
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
FOREIGN PATENT DOCUMENTS							
		Document Number	Date	Country	Class	Subclass	Translation Yes No
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
		Ezeamuzie C., et al., (1999) "Adenosine A3 receptors on human eosinophils mediate inhibition of degranulation and superoxide anion release", <u>British Journal of Pharmacology</u> , 127: 188-194 (Exhibit 90);					
		Fozard J., et al., (1996) "Mast cell degranulation following adenosine A3 receptor activation in rats", <u>European Journal of Pharmacology</u> , 298: 293-297 (Exhibit 91);					
		Franco M., et al., (1999) "Adenosine Regulates Renal Nitric Oxide Production in Hypothyroid Rats", <u>Journal of the American Society of Nephrology</u> , 1681-1688 (Exhibit 92);					
		Guerra L., et al., (1998) "Adenosine A3 receptor activation increases cytosolic calcium influx in A6 cells", <u>Nephrology Dialysis Transplantation</u> , 13 (6): A5 (Exhibit 93);					
		Jacobson K.A., et al., (1998) "Adenosine A3 receptors: novel ligands and paradoxical effects", <u>Tips</u> , 19:184-191 (Exhibit 94);					
		EXAMINER	DATE CONSIDERED			2/6/04	
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							



NOV 20 2003

CENTER 1600/2900

Page 11 of 13

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 60390-G/JPW/GJG/JBC		Serial No. 09/728,616	
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				Applicants: Arlindo L. Castelhana, et al.		Filing Date December 1, 2000	
				Group			
U.S. PATENT DOCUMENTS							
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
FOREIGN PATENT DOCUMENTS							
		Document Number	Date	Country	Class	Subclass	Translation Yes No
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
12		Jacobson K.A., et al., (1997) "Pharmacological Characterization of Novel A3 Adenosine Receptor-selective Antagonists", <u>Neuropharmacology</u> , 36 (9): 1157-1165 (Exhibit 95);					
		Lee T., et al., (2000) "Protective effects of renal ischemic preconditioning and adenosine pretreatment: role of A1 and A3 receptors", <u>Am. J. Physiol. Renal Physiol.</u> , 278: F380-F387 (Exhibit 96);					
		Ohana G., et al., (2001) "Differential Effect of Adenosine on Tumor and Normal Cell Growth: Focus on the A3 Adenosine Receptor", <u>Journal of Cellular Physiology</u> , 186: 19-23 (Exhibit 97);					
		Regulation of Downstream Effectors By GPCRs, (1999) <u>FASEB J.</u> , Abstracts 147.1-147.6 (Exhibit 98);					
		Reshkin J., et al., (2000) "Activation of A3 Adenosine Receptor Induces Calcium Entry and Chloride Secretion in A6 Cells", <u>J. Membrane Biol.</u> , 178: 103-113 (Exhibit 99);					
		Sawynok J., et al., (1997) "Adenosine A3 receptor activation produces nociceptive behaviour and edema by release of histamine and 5-hydroxytryptamine", <u>European Journal of Pharmacology</u> , 333: 1-7 (Exhibit 100);					
EXAMINER		DATE CONSIDERED 2/6/04					
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not-considered. Include copy of this form with next communication to applicant.							




RECEIVED

NOV. 2.0 2003

TECH CENTER 1600/2900

Page 12 of 13

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 60390-G/JPW/GJG/JBC		Serial No. 09/728,616	
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				Applicants: Arlindo L. Castelhana, et al.		Filing Date December 1, 2000	
				Group			
U.S. PATENT DOCUMENTS							
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
FOREIGN PATENT DOCUMENTS							
		Document Number	Date	Country	Class	Subclass	Translation Yes No
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
		Von Lubitz, D., et al., (1999) "Chronic administration of adenosine A3 receptor agonist and cerebral ischemia: neuronal and glial effects", <u>European Journal of Pharmacology</u> , 367: 157-163 (Exhibit 101);					
		Von Lubitz D., et al., (1999) "Stimulation of Adenosine A3 Receptors in Cerebral Ischemia", <u>Ann. NY. Acad. Sci.</u> , 890: 93-106 (Exhibit 102);					
		Yao Y., et al., (1997) "Adenosine A3 Receptor Agonists Protect HL-60 and U-937 Cells from Apoptosis Induced by A3 Antagonists", <u>Biochemical And Biophysical Research Communications</u> , 232: 317-322 (Exhibit 103); and					
		Zhao Z., et al., (2000) "A role for the A3 Adenosine receptor in determining tissue levels of cAMP and blood pressure: studies in knock-out mice", <u>Biochimica et Biophysica Acta</u> , 1500: 280-290 (Exhibit 104)					
		International Search Report for International Application No. PCT/US99/12135 (Exhibit 105); (December, 1999)					
	International Search Report for International Application No. PCT/US00/32702 (Exhibit 106) (June, 2001)						
		Lee T., et al., (1999) "Protective effects of renal ischemic preconditioning and adenosine pretreatment: role of A1 and A3 receptors", <u>72<sup>nd</sup> Scientific Sessions of the American Heart Association</u> , Atlanta, GA, p.197 (Exhibit 107);					
EXAMINER		DATE CONSIDERED 2/6/04					
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							



RECEIVED  
NOV 20 2003  
TECH CENTER 1600/2900

Page 13 of 13

Form PTO-1449  U.S. Department of Commerce Patent and Trademark Office  INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	Atty. Docket No. 60390-G/JPW/GJG/JBC	Serial No. 09/728,616
	Applicants: Arlind L. Castelhana, et al.	
	Filing Date December 1, 2000	Group

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
64	WO 9 8 2 9 3 9 7	7/9/98	PCT (Application with English abstract) (Exhibit 108);				
	WO 9 7 0 2 2 6 6	1/23/97	PCT (Exhibit 109);				
	IN 1 5 7 2 8 0	2/22/86	India (Exhibit 110);				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

74	Mautner, H.G., (1961) "Potential Deoxyribonucleic Acid Cross-linking Agents. 8,8'-Bisporines", J. Org. Chem. 26(6):1914-1917 (Exhibit 111); and
15	<del>PCT International Preliminary Examination Report for International Application No. PCT/US99/12135 (Exhibit 112).</del>

EXAMINER

DATE CONSIDERED

2/6/04

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449

U.S. Department of Commerce  
Patent and Trademark Office

Atty. Docket No.

60390-G/JPW/GJG/JBC

Serial No.

09/728,616

NOV 14 2003

INFORMATION DISCLOSURE CITATION  
(Use several sheets if necessary)

Applicants: Arlindo L. Castelhana, et al.

Filing Date

December 1, 2000

Group

1623

## U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
	09 4 5 4 0 7 5	12/2/99	Arlindo L. Castelhana, et al. (Exhibit 1);			
	09 4 5 4 0 7 4	12/2/99	Arlindo L. Castelhana, et al. (Exhibit 2);			
	20 02 00 58 6 6 7	5/16/02	Arlindo L. Castelhana, et al. (Exhibit 3);			
	20 03 00 36 5 4 5	2/20/03	Arlindo L. Castelhana, et al. (Exhibit 4);			
	20 02 00 28 7 8 2	3/7/02	Arlindo L. Castelhana, et al. (Exhibit 5);			
	20 03 00 45 5 3 6	3/6/03	Arlindo L. Castelhana, et al. (Exhibit 6);			
	20 03 00 73 7 0 8	4/17/03	Arlindo L. Castelhana, et al. (Exhibit 7);			
(E)	10 0 1 0 0 9 2	11/30/01	Arlindo L. Castelhana, et al. (Exhibit 8);			

## FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)


EXAMINER

DATE CONSIDERED

2/6/04

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



TECH CENTER 1600/2900 Page 1 of 1

U.S. Department of Commerce Patent and Trademark Office												Atty. Docket No. 60390-GJPW/GJG/JBC				Serial No. 09/728,616					
<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)																Applicants: Arlindo L. Castelhana, et al.					
																Filing Date December 1, 2000				Group 1624	

U.S. PATENT DOCUMENTS.																			
Examiner Initial	Date	Document Number	Name	Class	Subclass	Filing Date if Appropriate													

FOREIGN PATENT DOCUMENTS											
Date	Document Number	Country	Class	Subclass	Translation						
					Yes	No					


  

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	Bundy, G.L. et al. (1995) "Synthesis of Novel 2,4-Diaminopyrrolo-[2,3-d]pyrimidines with Antioxidant, Neuroprotective, and Antiasthma Activity" <u>J. Med. Chem.</u> 38: 4161-4163 ( <b>Exhibit 1</b> ).

EXAMINER	DATE CONSIDERED 8/7/03
----------	------------------------

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



[illegible]